Our Company

Aspiring to be the global leader in p53-targeted cancer therapies

Our Focus

Aprea Therapeutics Inc., (NASDAQ: APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics to reactivate the mutant tumor suppressor protein p53, the most commonly mutated gene in cancer.

Our Beginnings

Aprea was founded by Klas Wiman, Galina Selivanova, Vladimir Bykov, Staffan Strömblad, Wenjie Bao, Natalia Issaeva and Karolinska Innovations AB at the Karolinska Institute, based on the discovery of PRIMA-1 (p53 reactivation and induction of massive apoptosis). Subsequent enhancement of PRIMA-1 led to APR-246, also known as eprenetapopt, our lead product candidate.

Our Leadership

We have assembled an outstanding team, which includes world class scientific and clinical oncology leaders, to execute on our mission to create novel p53 reactivating therapies to help patients suffering with cancer. Together with our board of directors, our scientific founders and members of our management team have significant experience in drug discovery and development and finance. Collectively, we believe our team’s strong capabilities position us to build a leading biotech company focused on developing novel cancer therapies to address the significant unmet medical need of patients with p53 mutant malignancies, for whom there are limited effective therapeutic options.

Management Team

Christian S. Schade

President and Chief Executive Officer

Christian S. Schade has served as our President and Chief Executive and as a member of our board of directors since June 2016. Mr. Schade has more than 30 years of public and private pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in investment banking. Prior to joining Aprea, Mr. Schade was Chief Executive Officer of Novira Therapeutics Inc., a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson. He also served as Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceuticals company until it was purchased by AstraZeneca Plc. He previously held executive level positions at NRG Energy, serving as Executive Vice President and Chief Financial Officer, and as Senior Vice President Administration and Chief Financial Officer at Medarex Inc., until it was acquired by Bristol-Myers Squibb Co. He also held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade currently serves on the Board of Directors of Integra Life Sciences (NASDAQ: IART) where he chairs the Finance Committee, and on the Board of Directors of Sapience Therapeutics, a privately held company. He received an A.B. degree from Princeton University, and an M.B.A. from the Wharton School at the University of Pennsylvania.

Scott M. Coiante

Senior Vice President and Chief Financial Officer

Scott M. Coiante has served as our Senior Vice President, Chief Financial Officer since August 2019. Mr. Coiante joined Aprea from Agile Therapeutics, or Agile, where he was Senior Vice President and Chief Financial Officer. Having served at Agile since 2010, he played a leadership role in the company and in the development of the internal finance and accounting infrastructure. Prior to joining Agile, he was from 2002 Vice President of Finance and Treasurer at Medarex, Inc., formerly a NASDAQ listed biotech company that was acquired in 2009 by Bristol Myers Squibb. From 1989 to 2002, Mr. Coiante held management positions of increasing responsibilities at Ernst & Young LLP. Mr. Coiante received a B.S. in Accounting from Villanova University.

Eyal C. Attar, M.D.

Senior Vice President and Chief Medical Officer

Eyal C. Attar, M.D. has served as our Senior Vice President, Chief Medical Officer since April 2019. Dr. Attar joined Aprea from Agios Pharmaceuticals, where he was Senior Medical Director and IDH Hematology Medical Lead. Having served at Agios since 2014, Dr. Attar played a leadership role in the clinical development and approval of IDHIFA and TIBSOVO for patients with relapsed/refractory AML. Prior to Agios, he served on the clinical staff at the Massachusetts General Hospital Cancer Center, where Dr. Attar was a member of the Center for Leukemia and Assistant Professor of Medicine at Harvard Medical School. He completed his residency in Internal Medicine at Brigham and Women’s Hospital and held fellowships in hematology and oncology in the Dana-Farber Partners Cancer Care Hematology/Oncology Fellowship Program. Dr. Attar received his medical degree from the University of North Carolina School of Medicine.

Lars Abrahmsen, Ph.D.

Senior Vice President and Chief Scientific Officer

Lars Abrahmsen, Ph.D. has served as our Senior Vice President, Chief Scientific Officer since October 2014. Dr. Abrahmsen has more than 30 years of experience in research and drug development in the pharmaceutical industry, both with small molecules and biopharmaceuticals. Beginning with postdoctoral work at Genentech, he has also worked at Biovitrum, Pharmacia&Upjohn, Pharmacia and KabiGen. More recently he served as Chief Scientific Officer at Affibody from 2004-2010 and as SVP of Protein Therapeutics at Algeta from 2010-2013. Dr. Abrahmsen has experience from discovery research to preclinical development and has primarily focused on projects within oncology and metabolic diseases. Dr. Abrahmsen received a Ph.D. in Biochemistry and an M.S. in Chemistry, both from the Royal Institute of Technology in Stockholm, Sweden.

Gregory A. Korbel, Ph.D.

Vice President of Business Development

Gregory A. Korbel., Ph.D. has served as our Vice President of Business Development since July 2016. Dr. Korbel has 12 years of experience in the biotechnology and pharmaceutical industries. Prior to joining Aprea Therapeutics, he was Director of Business Development and Operations at Novira Therapeutics, which was acquired in December 2015 by Johnson & Johnson, and served as Director of Research Operations subsequent to the acquisition. In addition to consulting for venture capital and biotechnology firms, he formerly served as Senior Scientist at Invtirogen/Life Technologies. Dr. Korbel received an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in Chemistry from Harvard University and a B.A. from Vanderbilt University.

Board of Directors

Scott M. Rocklage, Ph.D.

Chairman

Scott M. Rocklage, Ph.D. has served as a member of our board of directors since 2016 and as Chairman of our board of directors since June 2017. Dr. Rocklage joined 5AM Ventures in 2003 as a Venture Partner, became a Managing Partner in 2004 and transitioned to Founding Partner in 2017. Dr. Rocklage has over three decades of healthcare management experience with strategic leadership responsibilities that led to FDA approval of three U.S. New Drug Applications (Omniscan™, Teslascan® and Cubicin®). He has served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar and has also held R&D positions at Salutar and Catalytica. Dr. Rocklage formerly served as Board Chairman of Relypsa (acquired by Vifor Pharma) and Novira (acquired by J&J). He currently serves as Board Chairman of Expansion, Kinestral and Cidara (NASDAQ: CDTX) and is a Board member at NodThera and Nouscom. He was formerly Executive Chairman of Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed) and Semprus (acquired by Teleflex). Dr. Rocklage received his B.S. in Chemistry from the University of California, Berkeley and his Ph.D. in Chemistry from MIT where he conducted research in the laboratory of Richard R. Schrock (Nobel Prize in Chemistry in 2005). He is an inventor or co-inventor of over 30 U.S. patents and has produced more than 100 peer-reviewed publications.

Christian S. Schade

President and Chief Executive Officer

Christian S. Schade has served as our President and Chief Executive and as a member of our board of directors since June 2016. Mr. Schade has more than 30 years of public and private pharmaceutical and biotechnology industry experience, as well as broad corporate finance expertise from his tenure in investment banking. Prior to joining Aprea, Mr. Schade was Chief Executive Officer of Novira Therapeutics Inc., a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson. He also served as Executive Vice President and Chief Financial Officer of Omthera Pharmaceuticals, Inc., an emerging specialty pharmaceuticals company until it was purchased by AstraZeneca Plc. He previously held executive level positions at NRG Energy, serving as Executive Vice President and Chief Financial Officer, and as Senior Vice President Administration and Chief Financial Officer at Medarex Inc., until it was acquired by Bristol-Myers Squibb Co. He also held various corporate finance and capital markets positions in New York and London for both Merrill Lynch and JP Morgan Chase & Co. Mr. Schade currently serves on the Board of Directors of Integra Life Sciences (NASDAQ: IART) where he chairs the Finance Committee, and on the Board of Directors of Sapience Therapeutics, a privately held company. He received an A.B. degree from Princeton University, and an M.B.A. from the Wharton School at the University of Pennsylvania.

Guido Magni, M.D., Ph.D.

Director

Guido Magni, M.D., Ph.D. has served as a member of our board of directors since March 2016. Dr. Magni has served a Partner with Versant Ventures since February 2012. Dr. Magni previously served as a Managing Director of EuroVentures, a Versant incubator, where he was intimately involved in several biotech investments including Synosia (sold to Biotie Therapies), Flexion and Okairos. Dr. Magni was previously the Global Head of the Medical Science Department of Roche Pharmaceuticals in Basel, Switzerland. During his twelve-year term at Roche, Dr. Magni oversaw the development and the registration of a large number of new chemical and biological entities including Cellcept, Pegasys, Mabthera, Xeloda, Herceptin, Tamiflu and Tarceva. Currently, Dr. Magni serves on the Board of Nouscom, Tarveda, Lava Therapeutics and Piqur, with previous board positions at Adolor Corporation, Anabasis Pharma and Biotie before their recent acquisitions. Dr. Magni was trained at the University of Padua with a specialization in neuro-psychiatry. He is the co-author of over 100 peer-reviewed papers.

Johan Christenson, M.D., Ph.D.

Director

Johan Christenson, M.D., Ph.D. has served as a member of our board of directors since 2016. Dr. Christenson is a Partner of HealthCap. Prior to joining HealthCap in 2001, Dr. Christenson was with SEB Företagsinvest (the venture capital arm of SEB) to supervise its health care portfolio. He has senior management experience from Astra Pain Control as Project Director and AstraZeneca as Global Product Director and member of the global therapy area management team of pain and inflammation. Dr Christenson serves on the boards of Targovax , InCarda and Fusion Pharmaceuticals. He previously served on the boards of Algeta (aquired by Bayer), Oncopeptides and CoreValve (aquired by Medtronic). Dr. Christenson received his medical training at the Karolinska Institute and received his Ph.D. in basic neuroscience in 1991. He served as a lecturer in neuroscience and also held a position as Assistant Dean at the Karolinska Institute Graduate School for two years. Dr. Christenson has four years of clinical specialist training in paediatrics and paediatric neurology.

Jonathan Hepple, Ph.D.

Director

Jonathan Hepple, Ph.D. has served as a member of our board of directors since April 2015. Dr. Hepple is a co-founder of Rosetta Capital Limited, where he has served as a Partner since January 2009. He has more than twenty years investment experience in the life sciences industry. He started his investment career at Rothschilds Asset Management and he was also a partner at Seroba Life Sciences where he was on the boards of Covagen and Opsona. Dr. Hepple has held Board Director and Observer roles in portfolio companies such as Catalyst Biosciences, Glycomimetics, Novimmune, Procertus and Tranzyme. He has served on the board of Clanotech AB since June 2013. He received his Ph.D. from Cambridge University for cancer research.

John B. Henneman

Director

John B. Henneman III has been a member of our board of directors since August 2019. Mr. Henneman has more than 25 years of combined financial and operational management experience in the life sciences industry. From July 2018 until November 2018, Mr. Henneman served as the Chief Administrative Officer of NewLink Genetics Corporation, a biotechnology company, and prior to that, served as NewLink’s Executive Vice President and Chief Financial Officer from October 2014 to July 2018. From 1998 to 2014, Mr. Henneman served at Integra LifeSciences Holdings Corp., a publicly-held medical device company, in various capacities. Before becoming Integra’s Chief Financial Officer in 2007, Mr. Henneman was Chief Administrative Officer, responsible for Integra’s regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions, the management of Integra’s surgical instruments business, and Integra’s business development function. Mr. Henneman serves on the boards of directors of R1 RCM, Inc., a publicly-held revenue cycle technology and management services company, SeaSpine Holdings Corporation, a publicly-held medical technology company, and Alafair Biosciences, Inc., a privately-held medical device company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm, and a consultant to SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies.

Bernd R. Seizinger, M.D., Ph.D.

Director

Dr. Bernd Seizinger, M.D., Ph.D., currently serves as chairman/board member in a number of public and private biotech companies in the U.S., Europe and Canada, including: Oxford BioTherapeutics, Aprea, CryptoMedix, Oncolytics and BioInvent. Previously he was President & CEO of GPC Biotech; VP Oncology Drug Discovery and – in parallel – VP Corporate and Academic Alliances at Bristol-Myers Squibb; Executive VP and CSO, Genome Therapeutics; Senior Faculty positions at Harvard Medical School, Massachusetts General Hospital and Princeton University.